评估用于强性化症治疗的替代化合物:从幼虫迁移抑制试验的新见解
María Cambra-Pellejà1,2, Elora Valderas-García1, Rafael Balaña-Fouce3
1Departamento de Sanidad Animal, Facultad de Veterinaria, Universidad de León, Campus de Vegazana, León, Spain.
PLoS neglected tropical diseases
|October 7, 2024
概括
新的候选药物显示出对抗强甲状腺瘤的前景,强甲状腺瘤是一种被忽视的热带疾病,影响数百万人. 研究人员开发了一种测试来选化合物,在实验室测试中发现新型衍生物比ivermectin更有效,为治疗提供了潜在的替代方案.
科学领域:
- 寄生虫学的寄生虫学
- 药物发现 药物发现 药物发现
- 被忽视的热带疾病被忽视
背景情况:
- 斯特朗基洛伊迪病影响全球6亿多人,是世卫组织2021-2030年路线图的重点.
- 使用ivermectin的大规模药物管理活动强调了由于潜在的耐药性而需要替代治疗方法.
研究的目的:
- 开发一种幼虫迁移抑制试验,用于评估虫杀虫剂的有效性.
- 为了选商业药物和新型二胺/氨基醇衍生物对*Strongyloides ratti*幼虫.
主要方法:
- 开发一种体外幼虫迁移抑制试验.
- 对六种商业药物,七种二胺衍生物和八种氨基醇衍生物的查.
- 确定半最大有效度 (EC50) 和选择性指数.
主要成果:
- 在经过测试的商业药物中,伊弗麦克丁和莫克西德克丁的EC50值是最高的.
- 与ivermectin相比,一些胺和氨基醇衍生物在抑制*S. ratti*运动方面表现出更高的有效性.
- 五种衍生品在HepG2和Caco2细胞上显示的选择性指数大于1.
结论:
- 新型二胺和氨基醇衍生物显示出作为强基化症的替代治疗方法的潜力.
- 这些化合物需要进一步的研究和体内疗效评估.
相关概念视频
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...